Brynte, Christoffer
Aeschlimann, Myriam
Barta, Csaba
Begeman, Alex Hendikus Abraham
Bäcker, Amanda
Crunelle, Cleo Lina
Daigre, Constanza
De Fuentes-Merillas, Laura
Demetrovics, Zsolt
Dom, Geert
López, Lara Grau
Icick, Romain
Johnson, Brian
Joostens, Peter
Kapitány-Fövény, Máté
Karsinti, Emily
Kiefer, Falk
Konstenius, Maija
Levin, Frances R.
Luderer, Mathias
Markus, Wiebren
Matthys, Frieda
Moggi, Franz
Palma-Alvarez, Raul Felipe
Paraskevopoulou, Maria
Ramos-Quiroga, J. Antoni
Schellekens, Arnt
Soravia, Leila M.
Therribout, Norman
Thomas, Anil
van de Glind, Geurt
van Kernebeek, Michiel Willem
Vollstädt-Klein, Sabine
Vorspan, Florence
van den Brink, Wim
Franck, Johan
Funding for this research was provided by:
Karolinska Institute
Article History
Received: 16 April 2022
Accepted: 12 September 2022
First Online: 23 September 2022
Declarations
:
: Participants received detailed written and oral study information before providing written informed consent. The study was approved by the Swedish Ethical Review Authority (2017/240–31) and was conducted in accordance with the Declaration of Helsinki – Ethical Principles for Medical Research Involving Humans Subjects.
: Not applicable.
: LGL has received speaker honorariums from Janssen-Cilag, Lundbeck, Servier, Otsuka, and Pfizer. RI has received honorarium by Pierre Fabre© paid directly to the non-profit association “Espace Murger”. FRL receives grant support from the NIDA, SAMHSA and US World Meds as well as a consultant for Major League Baseball. She also receives medication from Indivior for research. In addition, FRL was an unpaid member of a Scientific Advisory Board for Alkermes, Indivior, Novartis, Teva, and US WorldMeds but did not personally receive any compensation in the form of cash payments (honoraria/consulting fees) or food/beverage (she declined food/beverages in each circumstance) nor receive compensation in the form of travel reimbursement. ML received honoraria for talks and participation in advisory boards for Takeda and MEDICE / Arzneimittel Pütter GmbH. RFPA has received speaker honorariums from Angelini, Exeltis, Lundbeck, MSD, Mundipharma, and Takeda. J.A.R.Q was on the speakers’ bureau and/or acted as consultant for Janssen-Cilag, Novartis, Shire, Takeda, Bial, Shionogi, Sincrolab, Novartis, BMS, Medice, Rubió, Uriach and Raffo in the last 3 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, Rubió, Shire, Takeda, Shionogi, Bial and Medice. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following companies in the last 3 years: Janssen- Cilag, Shire, Oryzon, Roche, Psious, and Rubió. FV received congress fees paid by pharmaceutical companies (CAMURUS AB, RECORDATI, ACCORD Pharmaceutical) and funding received through a non-profit association for medical research (Association Robert Debré pour la Recherche Médicale).All other authors declare that they have no competing interests.